medigraphic.com
ISSN 1561-302X (Print)

2012, Number 2

<< Back Next >>

Rev cubana med 2012; 51 (2)

A century of antihypertensive therapy: Updating in the XXI century

León ÁJL, Pérez CMD

Language: Spanish
References: 48
Page: 155-169
PDF size: 80.74 Kb.


ABSTRACT

The availability of more safe and effective antihypertensive drugs has change the impact and the course of cardiovascular diseases including the high blood pressure. The XX century ended with great advances in the development of antihypertensive drugs with a proven effectiveness on the control of high blood pressure and the decrease of cardiovascular risk. In present paper authors made an historical rough outline on the research of high blood pressure during past century and also a review on the antihypertensive drugs under research during XXI century.


REFERENCES

  1. Wakerlin GE. From Bright toward light: The story of hypertension research. Circulation. 1962;26(1):1-6.

  2. Kempner W. Some effects of the rice diet treatment of kidney disease and hypertension. Bull N Y Acad Med. 1946;22(7):358-70.

  3. Torkildsen A. Neurosurgical treatment of essential hypertension. Acta Psychiatrica Scandinavica. 1934;9(3-4):489-93.

  4. Moser M. Historical perspectives on the management of hypertension. J Clin Hypertens. 2006;8(8 Suppl. 2):15-20.

  5. Freis ED, Wanko A, Wilson IM, Parrish AE. Treatment of essential hypertension with chlorothiazide (diuril). Its use alone and combined with other antihypertensive agents. J Am Med Assoc. 1958;166(2):137-40.

  6. Black JW, Stephenson JS. Pharmacology of a new adrenergic beta-receptor blocking compound (Nethalide). Lancet. 1962;2(7251):311-5.

  7. Piepho RW, Beal J. An overview of antihypertensive therapy in the 20th century. J Clin Pharmacol. 2000;40(9):967-77.

  8. Bühler FR, Laragh JH, Baer L, Vaughan ER Jr., Brunner HR. Propranolol inhibition of renin secretion a specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med. 1972;287(24):1209-14.

  9. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science. 1977;196(4288):441-4.

  10. Timmermans PB, Carini DJ, Chiu AT, Duncia JV, Price WA Jr, Wells GJ, et al. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am J Hypertens. 1991;4(4 Pt 2):275S-281S.

  11. Robinson SC, Brucer M. Range of normal blood pressure. A statistical and clinical study of 11,383 persons. Arch Int Med. 1939;64(3):409-44.

  12. WHO. Hypertension and coronary heart disease: Classification and criteria for epidemiological studies. First report of the Expert Committee on Cardiovascular Diseases and Hypertension. Wld Hlth Org Techn Rep Ser. 1959:168.

  13. Report of the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure: A cooperative study. JAMA. 1977;237(3):255-61.

  14. Macias Castro I. Modelo experimental de un programa de salud nacional para la atención integral del paciente con hipertensión arterial. Rev Cubana Med. 1975;14:7-64.

  15. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hipertensión. 2002;39(1):E1-8.

  16. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433-46.

  17. Mc Murray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1(1):17-24.

  18. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, et al. Effect of the direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients with Hypertension and Left Ventricular Hypertrophy. Circulation. 2009;119(4):530-7.

  19. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Lüscher TF. Vasopeptidase inhibitors: A new therapeutic concept in cardiovascular disease? Circulation. 2001;104(15):1856-62.

  20. Sagnella GA. Vasopeptidase inhibitors. J Renin Angiotensin Aldosterone Syst. 2002;3(2):90-5.

  21. Hamlyn JM, Manunta P. Endogenous ouabain: a link between sodium intake and hypertension. Curr Hypertens Rep. 2011;13(1):14-20.

  22. Blaustein MP, Zhang J, Chen L, Song H, Raina H, Kinsey SP, et al. The Pump, the exchanger, and endogenous ouabain: signaling mechanisms that link salt retention to hypertension. Hipertension. 2009;53(2):291-8.

  23. Ferrari P, Ferrandi M, Valentini G, Bianchi G. Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+-ATPase alterations in ouabain and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 2006;290(3):R529-35.

  24. Staessen JA, Thijs L, Stolarz-Skrzypek K, Bacchieri A, Barton J, Espositi ED, et al. Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo controlled phase 2 dose finding study of rostafuroxin. Trials. 2011;12:13.

  25. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol. 2007;152(5):567-75.

  26. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation. 2004;110(14):1996-2002.

  27. Lépicier P, Bibeau-Poirier A, Lagneux C, Servant MJ, Lamontagne D. Signaling pathways involved in the cardioprotective effects of cannabinoids. J Pharmacol Sci. 2006;102(2):155-66.

  28. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401(6750):282-6.

  29. Suguro T, Watanabe T, Ban Y, Kodate S, Misaki A, Hirano T, et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens. 2007;20(2):211-7.

  30. Tsoukas P, Kane, Giaid, A. Potential clinical implications of the urotensin II receptor antagonists. Front Pharmacol. 2011;2:38.

  31. Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, Matsuki M, et al. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation. 2005;112(17):2677-85.

  32. Wind S, Beuerlein K, Eucker T, Müller H, Scheurer P, Armitage ME, et al. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol. 2010;161(4):885-98.

  33. Goldblatt H, Haas E, Lamfrom H. Antirenin in man and animals. Trans Assoc Am Physicians. 1951;64:122-5.

  34. Downham MR, Auton TR, Rosul A, Sharp HL, Sjöström L, Rushton A, et al. Evaluation of two carrier protein angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol. 2003;56(5):505-12.

  35. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, et al. Effect of immunisation with CYT006-AngQb against angiotensin II on ambulatory blood pressure: a double-blind randomised placebo controlled phase IIa study. Lancet. 2008;371(9615):821-7.

  36. Fisher JP, Paton JFR. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J Hum Hypertens. 2011;1_13. doi: 10.1038/jhh.2011.66. [citado noviembre de 2011]. Disponible en: http://www.nature.com/jhh/journal/vaop/ncurrent/full/jhh201166a.html

  37. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275-81.

  38. Doumas M, Guo D, Papademetriou V. Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions. Expert Opin Ther Targets. 2009;13(4):413-25.

  39. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med. 1972;52(5):584-94.

  40. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953;1(6757):403-8.

  41. Tuckman J, Lyon AF, Reich T, Jacobson JH. 2nd. Evaluation of carotid sinus nerve stimulation in the treatment of hypertension. Ther Umsch. 1972;29(6):382-91.

  42. Scheffers I, Schmidli J, Kroon AA, Tordoir J, Mohaupt M, Allemann Y, et al. Sustained blood pressure reduction by baroreflex hypertension therapy with a chronically implanted system: 2-years data from the Rheos DEBUT-HT study in patients with resistant hypertension. J Hypertens. 2008;26 Suppl 1:S19.

  43. Hasenfuss G. New Generation Barostim neo™ System. Preliminary Results and Discussion. ESC 2011 Barostim Symposium. (Sitio en Internet). [citado 7 de noviembre de 2011]. Disponible en: http://www.cvrx.com/pdf/meetings/Hasenfuss_Slides_Final.pdf

  44. Ruilope LM, Dukat A, Böhm M, Lacourcičre Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255-66.

  45. Dhaun N, Webb DJ. Dual Endothelin-Converting Enzyme/Neutral Endopeptidase Inhibition: A Novel Treatment for Renovascular Hypertension Beyond Blood Pressure Lowering? Hipertensión. 2011;57(4):667-9.

  46. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland coronary prevention study group. N Engl J Med. 1995;333(20):1301-7.

  47. Nickenig G. Should Angiotensin II Receptor Blockers and Statins Be Combined? Circulation. 2004;110(8):1013-20.

  48. Kowala MC, Murugesan N, Tellew J, Carlson K, Monshizadegan H, Ryan C, et al. Novel Dual Action AT1 and ETA Receptor Antagonists Reduce Blood Pressure in Experimental Hypertension. J Pharmacol Exp Ther. 2004;309(1):275-84.




2020     |     www.medigraphic.com